<DOC>
	<DOCNO>NCT00969293</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single administration FOV2302 ( ecallantide ) patient macular edema associated central retinal vein occlusion .</brief_summary>
	<brief_title>Study Assess Safety Tolerability Single Administration FOV2302 ( Ecallantide ) Patients With Macular Edema Associated With Central Retinal Vein Occlusion</brief_title>
	<detailed_description>Occlusive retinal vascular disease uncommon . Central retinal vein occlusion ( CRVO ) second common vision-impairing vascular disorder retina follow diabetic retinopathy . Severe visual loss CRVO cause combination retinal edema neovascular proliferation ischemia . Vascular endothelial factor stimulate angiogenesis increase vascular permeability , major pathogenic factor CRVO . Counteracting neovascular effect provide significant therapeutic benefit subject suffer disorder . Macular edema condition result conjunction several , yet , partially unknown factor . Macular edema may occur disease cause cumulative injury many year , diabetic retinopathy , result acute event , branch retinal vein occlusion ( BRVO ) central retinal vein occlusion ( CRVO ) .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>Recent onset ( &lt; 6 month ) , nonischemic CRVO ( define association document retinal hemorrhage 4 quadrant retina dilate vein ) patient receive treatment condition ( e.g. , periocular depot intraocular treatment [ include corticosteroid antiVEGF ] , systemic corticosteroid laser hemodilution ) . Retinal thickness measure Stratus OCT &gt; 250Âµm central subfield study eye baseline . BCVA score ( measure ETDRS chart 5 letter ( 20/800 Snellen equivalent ) 65 letter ( 20/50 ) study eye baseline . Media clarity , pupillary dilation participant cooperation sufficient adequate fundus photograph . Females childbearing potential use adequate birth control Day 0 study completion . Patient able ( opinion investigator ) willing return schedule visit assessment . Ability read , understand willingness provide inform consent . Rubeosis iridis neovascular glaucoma baseline . Preretinal neovascularisation baseline . Ischemic CRVO , define 10 disc area nonperfusion fluorescein angiography baseline . Any grade diabetic retinopathy . Other eye condition could contribute macular edema cause retinal vascular change ( include vitreomacular traction , uveitis inflammatory disease , etc ) . Patients receive treatment condition ( e.g. , periocular depot intraocular treatment [ include corticosteroid antiVEGF ] , systemic corticosteroid laser hemodilution ) . Ocular surgery ( include cataract extraction , scleral buckle , etc . ) and/or YAG capsulotomy within 3 month precede treatment date anticipate within 3 month follow treatment administration . Poorly control ocular hypertension and/or glaucoma ( IOP great 25 mmHg despite maximal therapy ) . History par plana vitrectomy . Aphakia anterior chamber intraocular lens . Presence visible sclera thin ectasia . Presence substantial cataract medium opacity , opinion investigator , likely interfere visualization fundus completion study measurement . Any active ocular periocular infection ( include conjunctivitis , chalazion significant blepharitis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Macular Edema</keyword>
	<keyword>Occlusive retinal vascular disease</keyword>
	<keyword>Central Retinal Vein Occlusion</keyword>
	<keyword>CRVO</keyword>
</DOC>